CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced the closing of its initial public offering of 6,666,667 shares of its common stock at a price to the public of $15.00 per share. The gross proceeds from this offering, before deducting underwriting discounts and commissions and other offering expenses, are approximately $100,000,000. In addition, the underwriters have a 30-day option to purchase up to 1,000,000 additional shares of common stock at the initial public offering price less underwriting discounts and commissions. Magenta Therapeutics’ common stock began trading on the Nasdaq Global Market on June 21, 2018 under the symbol “MGTA.”
J.P. Morgan, Goldman Sachs & Co. LLC and Cowen are acting as joint book running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.
About Magenta Therapeutics
Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing therapeutics focused on critical areas of unmet need in the field of bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases.

